
Brexpiprazole Demonstrates Clinically Meaningful Improvements for Agitation Due to Alzheimer Disease
In May 2023, the FDA approved brexpiprazole as the first and only drug to receive approval for treatment of agitation associated with Alzheimer Disease dementia.



































